At a glance
ClinicalIndex Comparison RecordN/ACompleted· 28,118 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
In Brief
An observational study evaluating Tirzepatide and Semaglutide for Diabetes Mellitus, Type 2 and HFpEF - Heart Failure With Preserved Ejection Fraction. Completed, enrolled 28,118 participants across 1 site.
Detailed Summary
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20252026
Enrollment StartJan 2025
First PostedApr 2025
Primary CompletionJun 2025
TodayJul 2026
First PostedApr 6, 2025
Enrollment StartJan 14, 2025
Primary CompletionJun 1, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.2 years ago
Interventions
Tirzepatidedrug
New use of tirzepatide dispensing claim is used as the exposure.
Semaglutidedrug
New use of semaglutide dispensing claim is used as the reference.